Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Regulation of gene expression by signal transducer and activator of transcription 1 (STAT1) within host tissues mediates the antitumor effects of interferon alfa (IFN alpha). We used a novel flow cytometric assay to examine phosphorylation-mediated activation of STAT1 within immune effector cell subsets following in vitro or in vivo IFN alpha treatments. METHODS: Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors (n = 17) or melanoma patients (n = 19) were treated in vitro with interferon alfa-2b (IFN alpha-2b) or phosphate-buffered saline (PBS) and subjected to multiparametric flow cytometry to measure the levels of phosphorylated STAT1 (P-STAT1) within immune cell subsets. We similarly analyzed PBMCs isolated from melanoma patients before and 1 hour after immunotherapy with IFN alpha-2b. All statistical tests were two-sided. RESULTS: P-STAT1 levels in all major immune cell subsets increased within 15 minutes of in vitro IFN alpha-2b treatment of PBMCs; the increase was most pronounced in T lymphocytes and monocytes. Relatively low doses of IFN alpha-2b (i.e., 10(2)-10(3) IU/mL) induced maximal STAT1 activation in vitro. Compared with melanoma patients, healthy donors had higher basal levels of P-STAT1 (specific fluorescence [Fsp]; i.e., Fsp(PBS), the level of P-STAT1 in PBS-treated cells) in total PBMCs, natural killer (NK) cells, and T cells (mean Fsp(PBS) in total PBMCs: 5.5 in healthy donors versus 1.6 in patients, difference = 3.9, 95% confidence interval [CI] = 1.4 to 6.5, P =.004; mean Fsp(PBS) in NK cells: 4.6 in healthy donors versus 0.9 in patients, difference = 3.7, 95% CI = 1.7 to 5.7, P =.001; mean Fsp(PBS) in T cells: 6.8 in healthy donors versus 0.9 in patients, difference = 5.9, 95% CI = 2.5 to 9.3, P =.002). P-STAT1 was detected in the NK and T cells of two patients who received IFN alpha-2b immunotherapy (20 MU/m2 [MU = million units], administered by intravenous injection). P-STAT1 levels in the PBMCs of a patient treated sequentially with 5 MU/m2 and 10 MU/m2 IFN alpha-2b (administered by subcutaneous injection) also increased in response to treatments with IFN alpha-2b but did not increase further with the increased dosage of IFN alpha-2b. CONCLUSION: This flow cytometry method can be used to monitor STAT1 activation within subsets of immune cells from patients undergoing IFN alpha immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meraro, D., Gleit-Kielmanowicz, M., Hauser, H., & Levi, B.-Z. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6224 · Cited by 105
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215950 · Cited by 23
Self-citation
Cited by
Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.66 · Cited by 166
Self-citationIL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000328 · Cited by 100
Self-citationIL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. S., Campbell, A. R., Hu, Z., Tatum, A. S., Kondadasula, S. V., Mo, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0004 · Cited by 70
“Lysates were prepared from human pancreatic cancer cell lines as previously described (23, 24) and assayed for the expression of EGFR (Santa Cruz Biotechnology) or b-actin, as a loading control (Sigma-Aldrich).”
Self-citationWesolowski, R., Duggan, M. C., Stiff, A., Markowitz, J., Trikha, P., Levine, K. M., Schoenfield, L., Abdel-Rasoul, M., Layman, R., Ramaswamy, B., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2038-3 · Cited by 71
Self-citation
Metadata
- Authors
- Lesinski, G. B., Kondadasula, S. V., Crespin, T., Shen, L., Kendra, K., Walker, M., & Carson, W. E.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-31
- Volume
- 96
- Issue
- 17
- Pages
- 1331-1342
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2060736581
- Cited by
- 75
- References
- 2
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy. https://app.cochat.ai/papers/10.1093/jnci/djh252
- The paper
- Lesinski, G. B., Kondadasula, S. V., Crespin, T., Shen, L., Kendra, K., Walker, M., & Carson, W. E. (2004). Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh252
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.